Access and Affordability Initiative (AAI)

Partnership objectives

To gain understanding of whether differential pricing coupled with health system improvements is an effective tool to help improve access to medicines. 

The program will examine the role of differential pricing and health system strengthening to help improve access to medicines. The program will examine the role of differential pricing and health system strengthening to help improve access to medicines. Copyright Access Accelerated

What are the health need and challenges?

Non-communicable diseases (NCDs) are now the leading cause of death and disability worldwide, and the poorest and most vulnerable are most affected by these largely preventable diseases.

Having access to medicines to combat NCDs is a key factor for improving health and development in communities. Diseases, such as hypertension and diabetes together, affect more than 1 billion people in LMICs.   

Description of partnership activities and how they address needs and challenges

The Access and Affordability Initiative (AAI) is a global health collaboration between four pharmaceutical companies, MSD, Novartis, Pfizer and Sanofi, and the Gates Foundation.

The program will examine the role of differential pricing and health system strengthening to help improve access to medicines for underserved populations, particularly low-income groups, in LMICs. Differential pricing is a system that enables people to pay according to their means. To date, studies have mainly focused on measuring the impact of differential pricing between countries. The AAI pilot programs are exploring an innovative approach which measures the ability of patients living with NCDs in the same country to access medicines for these conditions when differential pricing is applied. The program will start with two pilot projects in Ghana and the Philippines, with around 3,000 people enrolled in each pilot.

MSD, Novartis, Pfizer and Sanofi is contributing financial support and project design consultation as well as differential pricing of medicines for use in the pilots. The Bill and Melinda Gates Foundation is contributing financial support for the development and implementation of evaluation programs for the two pilot projects, which are led by the Johns Hopkins Bloomberg School of Public Health. When the studies conclude in mid-2017, a team from Johns Hopkins University will measure the extent to which the approach is effective and sustainable. The companies will then decide whether to introduce differential pricing for NCD medicines on a wider scale in Ghana and the Philippines, or in other markets.

The AAI is one of the initiatives supporting Access Accelerated, a global partnership of a coalition of biopharmaceutical companies to address the barriers to access for NCDs in LMICs.


Videos

Access and Affordability Initiative in Palawan, the Philippines

Partnership information

Company(ies) MSD , Novartis , Pfizer , Sanofi

Partner(s) Bill and Melinda Gates Foundation, Bloomberg School of Public Health, Johns Hopkins University, Ghana Ministry of Health, Philippines Department of Health

Type of Partner(s) Academia / Hospitals, Government, NGOs

Therapeutic Focus Non-Communicable Diseases, Mental and Neurological Disorders, Women and Children's Health

Disease(s) Cardiovascular Diseases, Diabetes, Hypertension, Pneumonia

Program Type(s) Availability of Treatment - Differential Pricing, Health System Infrastructure - Outreach & Medical Services

Region(s) Middle East & North Africa

Number of Countries 2

Country(ies) Ghana, Philippines

Start Date 2016

More information Access Accelerated

Anticipated completion date 2017